SCHEMBL6203345

SCHEMBL6203345

O=C(CC(c1ccccc1)S(=O)(=O)c1ccccc1)c1ccccc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.74
NPC1 O15118 3/20 0.74
RAB9A P51151 3/20 0.74
SMN1; SMN2 Q16637 3/20 0.74
TDP1 Q9NUW8 1/20 0.74
LMNA P02545 3/20 0.64
MAPT P10636 3/20 0.64
KDM4E B2RXH2 3/20 0.56
L3MBTL1 Q9Y468 2/20 0.56
KMT2A Q03164 4/20 0.54
MEN1 O00255 3/20 0.54
PDE4A P27815 4/20 0.50
PDE4B Q07343 4/20 0.50
PDE4C Q08493 4/20 0.50
PDE4D Q08499 4/20 0.50
MMP2 P08253 1/20 0.50
MMP3 P08254 1/20 0.50
GAA P10253 1/20 0.49
HTT P42858 1/20 0.49
TSHR P16473 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29160363 0.90 ALDH1A1 (0.79) ALDH1A1NPC1RAB9ASMN1; SMN2TDP1
SCHEMBL5053827 0.90 ALDH1A1 (0.62) ALDH1A1NPC1RAB9ASMN1; SMN2TDP1
SCHEMBL667296 0.90 ALDH1A1 (0.62) ALDH1A1NPC1RAB9ASMN1; SMN2TDP1
SCHEMBL29160472 0.86 ALDH1A1 (0.90) ALDH1A1NPC1RAB9ASMN1; SMN2TDP1
SCHEMBL22362036 0.84 KMT2A (0.56) ALDH1A1NPC1RAB9ASMN1; SMN2TDP1
SCHEMBL22014067 0.83 TSHR (0.56) ALDH1A1NPC1RAB9ASMN1; SMN2TDP1
SCHEMBL6677049 0.83 TSHR (0.56) ALDH1A1NPC1RAB9ASMN1; SMN2TDP1
SCHEMBL22014331 0.83 TSHR (0.56) ALDH1A1NPC1RAB9ASMN1; SMN2TDP1
SCHEMBL6673825 0.81 TSHR (0.55) ALDH1A1NPC1RAB9ASMN1; SMN2TDP1
SCHEMBL29160275 0.81 ALDH1A1 (0.67) ALDH1A1NPC1RAB9ASMN1; SMN2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120029197-A1 Method for Preparing Sulfur-Containing Compounds THE ROYAL COLLEGE OF SURGEONS IN IRELAND (IE) 2012-02-02 US disclosed
WO-2010066450-A1 A METHOD FOR PREPARING SULFUR-CONTAINING COMPOUNDS THE ROYAL COLLEGE OF SURGEONS IN IRELAND (IE) 2010-06-17 WO disclosed
US-20050272036-A1 Ketones ASTRAZENECA AB (SE) 2005-12-08 US disclosed
CN-1681763-A Chemical compounds ASTRAZENECA AB (SE) 2005-10-12 CN disclosed
EP-1549600-A1 KETONES AstraZeneca AB (SE) 2005-07-06 EP disclosed
WO-2004011410-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2004-02-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120029197-A1 Method for Preparing Sulfur-Containing Compounds SULT1E1, SULT1A1, TST ALDH1A1 195/4885NPC1 2488/4885RAB9A 2458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.